Bispecific antibodies (BsAb) can, by virtue of combining two binding specificities, improve the selectivity and efficacy of antibody-based treatment of human disease. Antibodies with two distinct binding specificities have great potential for a wide range of clinical applications as targeting agents for in vitro and in vivo immunodiagnosis, therapy and for improving immunoassays. They have shown great promise for targeting cytotoxic effector cells, delivering radionuclides, toxins or cytotoxic drugs to specific targets, particularly tumour cells. The development of BsAb research goes through three main stages: chemical cross linking of murine-derived monoclonal antibody, hybrid hybridomas and engineered BsAb. This article is providing the potential applications of bispecific antibodies.
Brief History
In the first decade of this century Paul Ehrlich proposed the idea of using 'bodies' which possess a particular affinity for a certain organ [1] . The introduction of hybridoma technology for producing monoclonal antibodies [2] has revolutionized almost every field of modern medicine, including tumour targeting. Monoclonal antibodies seem to be the ideal 'magic bullets' for specific targeting of tumours.
What is Antibody?
Antibodies (also known as immunoglobulins, abbreviated Ig) are gamma globulin proteins that are found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as and viruses. They are typically made of basic structural units-each with two large heavy chains and two small light chains -to Bispecific Antibody form a "Y" shaped molecule. This variable region,
The potential for using monoclonal antibodies composed of 110-130 amino acids, give the antibody (MAb) to enhance the capacity of the immune system its specificity for binding antigen. The variable region to combat tumors and infectious disease has includes the ends of the light and heavy chains. stimulated imagination for the last 25 years [3] . In Applications of bispecific antibodies order to improve the therapeutic utility of antibodies 1) Immunoassay different modifications have been suggested. One of 2)
Tumor targeting these concerns the generation of BsAb [4] . Harmsen 3) Clinical application in cancer [5] developed an immunotherapy using Bispecific 4) Immunotherapy antibody that confers rapid protection against FMD in 5) Radioimmunotherapy outbreak situations.
6) Drug/toxin/cytokine targeting Immunotherapy of non-Hodgkin's B cell lymphoma with bispecific antibody construct has the 1) Immunoassays: The effector binding arm can potential to engage all cytotoxic T cells [6] . Bispecific be designed to have specificity for marker enzymes or monoclonal antibody (BsMAb), first introduced by other indicator systems. The anti-target-anti-peroxidase Nisonoff and Rivers into the academia 40 years ago, is bispecific antibodies which have been used in a unique type of MAb with two different binding immunohistochemistry have led to improvements in specificities within a single molecule. Bispecific sensitivity, signal-to-noise ratio, and simplification of antibodies which have two different antigen-specific staining procedures with preservation of fine ultra binding sites, one for tumour-associated antigen structural detail. (target binding arm) and the other for the effector
2)
Tumour targeting: The use of bispecific compounds (effector binding arm), have been antibodies for immunodiagnosis and therapy has developed. They can be used for any application in shown some encouraging results. They have been used which two molecules need to be juxtaposed within a for delivering effector substances such as toxins and distance of a few nM. cytotoxic drugs to tumours, and some are now in BsMAb holds great promise for numerous therapeutic clinical trials. needs in the light of: 1.
Recent breakthroughs in recombinant DNA 3) Clinical application in cancer: Immunotherapy technology, is a powerful anti-cancer treatment modality. Using 2.
The increased number of identified disease BsAbs, it is possible to take advantage of the highly specific binding characteristics of antibodies and targets as the result of the completion of human combine these with the powerful effector functions of genomic map project, and cytotoxic immune effector cells. BsAbs share two 3.
A better understanding of the mechanism of different, monoclonal antibody-derived, antigenhuman immune system. recognizing moieties within one molecule. By dual A bsAb promotes the formation of conjugates binding, BsAbs reactive with a trigger molecule on an between effectors and target cells by binding to a immune effector cell on the one hand and a surface surface molecule on each cell type. If total random antigen on a tumor target cell on the other are thus able association of heavy and light chains occurs, ten to functionally focus the lytic activity of the immune different combinations of immunoglobulin molecules effector cell towards the target cell [8] . are generated; however, only one has the desired bispecific activity (Fig.-1) . Fusions have been done
4)
Radioimmunotherapy: Conventional radiobetween pairs of hybridoma cell lines secreting two immunotherapy (RIT) using systemically administered existing monoclonal antibodies [7] .
MAb linked to radionuclides is a promising approach to metastatic cancer treatment. However, conventional RIT with MAb conjugates damages critical organs due to exposure to high radiation dose from long circulating radiolabeled antibody and non-specific accumulation of radiolabeled antibody in exposed organs. Pretargeted radioimmunotherapy with BsMAb is a multi-step strategy that allows quick and specific delivery of radioisotope (Y, I, Re and P) to a tumor with minimal radiation exposure, hence lowered toxicity to normal organs.
Fig.1 Diagrammatic representation of immunoglobulin
Pretargeting RIT combines long-circulating molecules secreted by a hybrid hybridomas cell as a result of
BsMAb and small, rapidly-excreted molecules to random association of heavy and light chain from both achieve a high tumor-to-blood ratio. Bispecific antibodies are manufactured or 7. In 2011 Schaefer correctly assemble two heavy engineered from two separate antibodies to create a and two light chains, derived from two existing molecule with two different binding specificities. antibodies, to form human bivalent bispecific IgG These are used to link a target to trigger molecules on antibodies without use of artificial linkers. Applying effector cells of the immune system. This shows the three possible "CrossMab" formats, they outlines the preparation of bispecific antibodies, generated bispecific antibodies against angiopoietin-2 describes the components of cellular cytotoxicity in (Ang-2) and vascular endothelial growth factor A the immune system [11] .
(VEGF-A) and show that they can be produced by 3.
The use of bispecific antibodies as possible standard techniques, exhibit stabilities comparable to therapeutic agents for cancer treatment was proposed natural antibodies, and bind both targets simultaneously in the mid-1980s [12] . The common strategy for with unaltered affinity. Because of its superior side-CH1-CL making bispecific antibodies involves combining the product profile, the CrossMab was selected for in variable domains of the desired mAbs into a single vivo profiling and showed potent antiangiogenic and bispecific structure. Many different formats of antitumoral activity [16] . bispecific antibodies have been generated within the 8.
In 2010 Robert describes a new procedure for research field of bispecific immunotherapeutics, forming multivalent and/or multispecific proteins, including the chemical heteroconjugation of two known as the dock-and-lock (DNL) technique. This complete molecules or fragments of MAbs, methodology has the flexibility to create a number of quadromas, F(ab')2, diabodies, tandem diabodies and other biologic agents of therapeutic interest. A variety single-chain antibodies.
of constructs, based on anti-CD20 and CD22 4.
Jackman and their co workers [13] had applied a antibodies, have been made, with results showing that technology to generate a bispecific antibody suitable multispecific antibodies have very different properties for development as a human therapeutic. This from the respective parental monospecific antibodies. antibody directly inhibits the activation of the high Thus, DNL technology is a highly flexible platform affinity IgE receptor FcγRI on mast cells and basophils that can be used to prepare many different types of by cross-linking FcγRI with the inhibitory receptor agents that could further improve cancer detection and FcγRIIb, an approach that has strong therapeutic therapy [17] . potential for asthma and other allergic diseases.
9. In 2011 Schanzer described novel tetravalent, 5.
In 2010 Wang and their coworker report that the bispecific antibody derivatives that bind two different natural bispecific antibody can also be generated in epitopes on the HIV coreceptor CCR5. In contrast to New Zealand white rabbits by immunization with monospecific CCR5 antibodies, bispecific antibody synthesized conjugates. These antibodies showed derivatives block two alternative docking sites of bispecificity to the components that were CCR5-tropic HIV strains on the CCR5 coreceptor. simultaneously used to immunize the animals. Wang Consequently, these molecules showed 18-to 57-fold observed a trend in test animals that female rabbits increased antiviral activities compared to the parent exhibited stronger bispecific antibody responses than antibodies. Most importantly, one prototypic tetravalent males. The bispecific antibody was monomeric and CCR5 antibody had antiviral activity against virus primarily belonged to immunoglobulin (Ig) G. strains resistant to the single parental antibodies. In Moreover, bispecific antibodies were demonstrated by summary, physical linkage of two CCR5 antibodies mixing 2 purified monospecific antibodies in vivo and targeting different epitopes on the HIV coreceptor in vitro [14] .
CCR5 resulted in tetravalent, bispecific antibodies 6.
In 2010 Kammila and their co workers worked with enhanced antiviral potency against wild-type and for the detection of severe acute respiratory syndrome CCR5 antibody-resistant HIV-1 strains [18] . www.veterinaryworld.org Veterinary World, Vol.5 No.12 December 2012 10. In 2011 wang and jinming identified the presence potential therapeutic target antigens from <400 to of natural bispecific antibodies against cyclic <4,000. We anticipate that BsAb will play a significant citrullinated peptide (CCP) and immunoglobulin G role in therapies directed to some of these novel (IgG) 
